Gregory T. Everson

25.3k total citations · 3 hit papers
264 papers, 14.4k citations indexed

About

Gregory T. Everson is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Gregory T. Everson has authored 264 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Hepatology, 159 papers in Epidemiology and 69 papers in Surgery. Recurrent topics in Gregory T. Everson's work include Liver Disease Diagnosis and Treatment (149 papers), Hepatitis C virus research (121 papers) and Liver Disease and Transplantation (95 papers). Gregory T. Everson is often cited by papers focused on Liver Disease Diagnosis and Treatment (149 papers), Hepatitis C virus research (121 papers) and Liver Disease and Transplantation (95 papers). Gregory T. Everson collaborates with scholars based in United States, Germany and United Kingdom. Gregory T. Everson's co-authors include Igal Kam, James F. Trotter, Anna S. Lok, Michael Wachs, Adrian M. Di Bisceglie, Timothy R. Morgan, Herbert L. Bonkovsky, William M. Lee, Mitchell L. Shiffman and Marc G. Ghany and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Gregory T. Everson

259 papers receiving 13.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

2009 803 citations John G. McHutchison, Gregory T. Everson et al. profile →
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

2011 566 citations David R. Nelson, Mark Sulkowski et al. profile →
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

2012 454 citations Anna S. Lok, Gregory T. Everson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory T. Everson United States	63	10.1k	8.6k	3.8k	1.1k	1.1k	264	14.4k
Frederik Nevens Belgium	62	9.2k 0.9×	7.8k 0.9×	5.6k 1.5×	1.7k 1.6×	2.0k 1.9×	435	15.4k
Hugo R. Rosen United States	62	7.9k 0.8×	6.8k 0.8×	2.1k 0.6×	1.2k 1.1×	1.5k 1.4×	196	13.8k
Nigel Heaton United Kingdom	67	8.0k 0.8×	4.9k 0.6×	9.1k 2.4×	1.8k 1.7×	1.7k 1.6×	505	16.0k
Bernard Portmann United Kingdom	71	9.3k 0.9×	8.1k 0.9×	4.8k 1.3×	1.2k 1.1×	946 0.9×	232	14.6k
Giorgina Mieli‐Vergani United Kingdom	76	11.7k 1.2×	9.2k 1.1×	8.1k 2.1×	2.1k 2.0×	1.4k 1.3×	509	21.0k
Daniel Dhumeaux France	63	13.8k 1.4×	12.1k 1.4×	2.4k 0.6×	1.4k 1.3×	1.1k 1.0×	283	17.9k
François Durand France	64	12.8k 1.3×	9.8k 1.1×	7.3k 1.9×	1.1k 1.0×	1.1k 1.0×	368	17.7k
Claude Degott France	77	8.3k 0.8×	8.3k 1.0×	3.3k 0.9×	2.4k 2.2×	2.7k 2.5×	318	18.1k
Calogero Cammà Italy	62	7.5k 0.7×	8.4k 1.0×	2.3k 0.6×	1.3k 1.2×	586 0.5×	271	12.0k
Richard K. Sterling United States	66	13.7k 1.3×	15.8k 1.8×	4.4k 1.2×	711 0.7×	2.1k 1.9×	326	20.6k

Countries citing papers authored by Gregory T. Everson

Since Specialization

Citations

This map shows the geographic impact of Gregory T. Everson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory T. Everson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory T. Everson more than expected).

Fields of papers citing papers by Gregory T. Everson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory T. Everson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory T. Everson. The network helps show where Gregory T. Everson may publish in the future.

Co-authorship network of co-authors of Gregory T. Everson

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory T. Everson. A scholar is included among the top collaborators of Gregory T. Everson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory T. Everson. Gregory T. Everson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McRae, Michael P., et al.. (2024). Within‐individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test. Clinical and Translational Science. 17(4). e13786–e13786. 12 indexed citations

Shiffman, Mitchell L., K. Rajender Reddy, Michael D. Leise, et al.. (2024). Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT‐V Study. Alimentary Pharmacology & Therapeutics. 61(1). 75–87. 5 indexed citations

Hassanein, Tarek, Andrew P. Keaveny, Parvez Mantry, et al.. (2024). Liver function and portal‐systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices. Alimentary Pharmacology & Therapeutics. 60(2). 246–256. 10 indexed citations

Kanodia, Jitendra, Hugh Giovinazzo, David L. Bourdet, et al.. (2024). Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child‐Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine. Clinical Pharmacology & Therapeutics. 116(1). 186–193. 2 indexed citations

Verna, Elizabeth C., Marina Serper, Jaime Chu, et al.. (2020). Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation. Hepatology. 72(5). 1819–1837. 16 indexed citations

Burton, James R., Norah A. Terrault, David S. Goldberg, et al.. (2019). Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation. 104(3). 476–481. 19 indexed citations

Rower, Joseph E., James R. Burton, Peter L. Anderson, et al.. (2015). Population Pharmacokinetic Modeling of Plasma and Intracellular Ribavirin Concentrations in Patients with Chronic Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy. 59(4). 2179–2188. 25 indexed citations

Everson, Gregory T., William Towner, Mitchell Davis, et al.. (2015). Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection. Annals of Internal Medicine. 4 indexed citations

Verna, Elizabeth C., James R. Burton, Jacqueline G. O’Leary, et al.. (2013). 23 A MULTICENTER STUDY OF PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS: REPORT FROM THE CRUSH-C GROUP. Journal of Hepatology. 58. S10–S11. 18 indexed citations

10.

Shiffman, Mitchell L., Chihiro Morishima, Jules L. Dienstag, et al.. (2009). Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology. 137(6). 1986–1994. 30 indexed citations

11.

Lok, Anna S., Leonard B. Seeff, Timothy R. Morgan, et al.. (2008). Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. Gastroenterology. 136(1). 138–148. 452 indexed citations

12.

Nelson, David R., Gary L. Davis, Ira M. Jacobson, et al.. (2008). Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy. Clinical Gastroenterology and Hepatology. 7(4). 397–414. 11 indexed citations

13.

McHutchison, John G., Gregory T. Everson, S. Gordon, et al.. (2007). [786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C. Journal of Hepatology. 46. S296–S296. 19 indexed citations

14.

Balan, Vijayan, David R. Nelson, Mark Sulkowski, et al.. (2006). Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.. PubMed. 11(7). 901–8. 12 indexed citations

15.

Fontana, Robert J., Arun J. Sanyal, Savant Mehta, et al.. (2006). Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial. The American Journal of Gastroenterology. 101(5). 983–992. 53 indexed citations

16.

Hayashi, Paul H., James F. Trotter, & Gregory T. Everson. (2003). Hepatocellular carcinoma extension into the right atrium. Liver Transplantation. 9(11). 1225–1226. 1 indexed citations

17.

Trouillot, T, Daniel G. Pace, C McKinley, et al.. (2001). Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. The American Journal of Gastroenterology. 96(6). 1888–1894. 22 indexed citations

18.

Jarvis, Catherine, et al.. (1999). TOTAL PARENTERAL NUTRITION AND CHOLESTASIS. Clinics in Liver Disease. 3(3). 489–508. 33 indexed citations

19.

Sokol, Ronald J., James M. McKim, Stephanie Z. Ruyle, et al.. (1998). Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology. 114(1). 164–174. 164 indexed citations

20.

Reveille, R. Matthew, Gregory V. Stiegmann, & Gregory T. Everson. (1990). Increased secondary bile acids in a choledochal cyst. Gastroenterology. 99(2). 525–527. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact